Search results

Back
1 - 10 of 30 Search results
    - 

 - 

Ipsen to Highlight Expanded Oncology Portfolio and Advances in Follicular Lymphoma Research at ASH 2022

November 3, 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) will highlight its expanded portfolio in hematology at the American Society of Hematology (ASH) Annual Meeting from December 10-13 following its recent acquisition of Epizyme. The company will sha...


    -   - 5 mins read

 -   - 5 mins read

‘A Life in a Day’: the realities of living with FOP

I was honored to be invited to take on the challenge to live ‘A Life in a Day of a patient with FOP’ – but also apprehensive. The challenge simulated a day spent living as someone who has fibrodysplasia ossificans progressiva (FOP). FOP is a debilita...


    - 

 - 

Ipsen announces results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancer

PARIS, FRANCE, 03 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III RESILIENT trial did not meet its primary endpoint of overall survival (OS) compared to topotecan. The trial is evaluating Onivyde® (irinotecan...


    - 

 - 

Ipsen Sponsors Pancreatic Cancer Action Network’s Purplestride Walk

Cambridge, Massachusetts (April 19th, 2022)—Ipsen supports Pancreatic Cancer Action Network (PanCAN) as a national sponsor of the organization’s PanCAN PurpleStride, their event to end pancreatic cancer. On April 30, 60 communities acros...


    -   - 2 mins read

 -   - 2 mins read

Our pledge: summaries in plain language for all journal publications

Today, we are broadening our commitment to providing everyone with the opportunity to read and understand our research. From July 2022, we will publish, as a minimum, a 250-word plain language summary alongside all company-sponsored journal publications fr...


    - 

 - 

Ipsen appoints Stewart Campbell Executive Vice President and President of North America

CAMBRIDGE, Massachusetts, November 3, 2021 — Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Stewart Campbell as Executive Vice President and President of North America, effective immediately. Based in Cambridge, he will lead th...


    - 

 - 

Multi-National PRESTO Study Presented by ENETS with Simultaneous Publication in Advances in Therapy

– In PRESTO, almost all nurse participants (97.8%) reported a preference* for the Somatuline® Depot(lanreotide) redesigned pre-filled syringe compared with the syringe for long-acting release octreotide–CAMBRIDGE, Mass. March 11, 2020 — Ipsen Biopha...


    - 

 - 

Ipsen Announces FDA Approval of Dysport®(abobotulinumtoxinA) for the Treatment of Upper LimbSpasticity in Children, Excluding Cerebral Palsy

– Dysport is the first and only FDA-approved botulinum toxin for treatment of both pediatricupper and lower limb spasticity1 –– Pivotal Phase 3 study demonstrated Dysport improved spasticity symptoms in children agedtwo to 17 experiencing upper limb ...


    - 

 - 

Ipsen Announces U.S. FDA Approval for Newly DesignedPre-Filled Syringe for Somatuline® Depot (lanreotide)

– New Syringe Designed to Help Enhance Injection Experience –Cambridge, Mass., June 24, 2019 – Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR:IPSEY), announced today that the United States Food and Drug Administration (FDA) has a...


    - 

 - 

Ipsen Celebrates Opening of New Cambridge Headquarters with Day of Service

– Ipsen officially opens North American headquarters at One Main Street and recently renovatedR&D and Global External Innovation and Partnering facilities at 650 East Kendall Street –– More than 115 employees join together to support nine local n...


1 2 3